| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Diagonal Bio AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.0025 |
| 52 Week High | kr0.063 |
| 52 Week Low | kr0.0023 |
| Beta | 0.50 |
| 11 Month Change | -10.71% |
| 3 Month Change | -64.79% |
| 1 Year Change | -89.04% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9F1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -3.8% | 4.0% | 0.008% |
| 1Y | -89.0% | -19.3% | 3.1% |
Return vs Industry: 9F1 underperformed the German Biotechs industry which returned -19.3% over the past year.
Return vs Market: 9F1 underperformed the German Market which returned 3.1% over the past year.
Price Volatility
| 9F1 volatility | |
|---|---|
| 9F1 Average Weekly Movement | 29.3% |
| Biotechs Industry Average Movement | 5.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 9F1's share price has been volatile over the past 3 months.
Volatility Over Time: 9F1's weekly volatility (29%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 4 | Karin Wehlin | diagonalbio.com |
Diagonal Bio AB (publ) operates as a biotechnology company in Sweden. The company offers LAMPlify, a customized system for general laboratory use to identify the presence of specific genetic markers for, for example, fungi, viruses, or bacteria. It is also involved in the development of PANVIRAL, a universal in vitro diagnostic system, that offers the potential for rapid and accurate point-of-care diagnoses in various settings, such as doctor’s office, surgery, mobile clinics, hospital bedsides, and workplaces and airports.
Diagonal Bio AB (publ) Fundamentals Summary
| 9F1 fundamental statistics | |
|---|---|
| Market cap | €1.10m |
| Earnings (TTM) | -€975.55k |
| Revenue (TTM) | €210.75k |
5.2x
P/S Ratio-1.1x
P/E RatioIs 9F1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9F1 income statement (TTM) | |
|---|---|
| Revenue | kr2.37m |
| Cost of Revenue | kr18.00k |
| Gross Profit | kr2.35m |
| Other Expenses | kr13.33m |
| Earnings | -kr10.97m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 22, 2024
| Earnings per share (EPS) | -0.027 |
| Gross Margin | 99.24% |
| Net Profit Margin | -462.88% |
| Debt/Equity Ratio | 0% |
How did 9F1 perform over the long term?
See historical performance and comparison